Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 1, 2006, Pages

  Banes Berceli, Amy K ^a   Shaw, Sean ^a   Ma, Guochuan ^a   Brands, Michael ^a   Eaton, Douglas C ^b   Stern, David M ^c   Fulton, David ^a   Caldwell, R William ^a   Marrero, Mario B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Nephropathy; Rho GTPase

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 4; GLUCOSE; ISOPRENOID; JANUS KINASE; JANUS KINASE 2; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MESANGIUM; MESANGIUM CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 33745410215     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00502.2005     Document Type: Article

References (18)

1. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, and Marrero MB. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 61: 1605-1616, 2002.
2. Amiri F, Venema VJ, Wang X, Ju H, Venema RC, and Marrero MB. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 274: 32382-32386, 1999.
3. Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, and Marrero MB. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286: F653-F659, 2004.
4. Da Ros R, Assaloni R, and Ceriello A. Antioxidant therapy in diabetic complications: what is new? Curr Vasc Pharmacol 2: 335-341, 2004.
5. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, and Kanwar YS. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 99: 8301-8305, 2002.
6. Epstein M and Campese VM. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45: 2-14, 2005.
7. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, and Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107: 106-112, 2003.
8. Kim SI, Han DC, and Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11: 80-87, 2000.
9. Linsel-Nitschke P and Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4: 193-205, 2005.
10. Malcolm J, Meggison H, and Sigal R. Prevention of cardiovascular events in diabetes. Clin Evid 10: 690-714, 2003.
11. Ojeda LA, Gutierrez JL, and Salazar E. Dyslipidemia in the elderly. Arch Cardiol Mex 74: 315-326, 2004.
12. Padwal R, Majumdar SR, Johnson JA, Varney J, and McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28: 736-744, 2005.
13. Paulo S, Fernandes S, Vizinho R, and Carneiro AV. Statin therapy in the primary and secondary prevention of coronary artery disease in patients with type 2 diabetes. A scientific review. Rev Port Cardiol 23: 1461-1482, 2004.
14. Pelletier S, Duhamel F, Coulombe P, Popoff MR, and Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol Cell Biol 23: 1316-1333, 2003.
15. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, and Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003.
16. Wang X, Shaw S, Amiri F, Eaton DC, and Marrero MB. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505-3509, 2002.
17. Woodman RJ, Chew GT, and Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 65: 31-74, 2005.
18. Zeng L, Xu H, Chew TL, Chisholm R, Sadeghi MM, Kanwar YS, and Danesh FR. Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. J Am Soc Nephrol 15: 1711-1720, 2004.